Publication:
The impact of previous sars-cov-2 infection on post-vaccine adverse events in individuals vaccinated with turkovac or coronavac -inactivated covid-19 vaccines

dc.contributor.authorTanrıöver, Mine Duruşu
dc.contributor.authorAydın, Özlem Altuntas
dc.contributor.authorGüner, Rahmet
dc.contributor.authorYıldız, Orhan
dc.contributor.authorÇelik, İlhami
dc.contributor.authorKöse, Şükran
dc.contributor.authorAkhan, Sila
dc.contributor.authorÖzdarendeli, Aykut
dc.contributor.authorÜnal, Serhat
dc.contributor.authorAteş, Ihsan
dc.contributor.authorKara, Ateş
dc.contributor.buuauthorAKALIN, EMİN HALİS
dc.contributor.departmentTıp Fakültesi
dc.contributor.departmentEnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Ana Bilim Dalı.
dc.contributor.orcid0000-0001-7530-1279
dc.contributor.researcheridAAU-8952-2020
dc.contributor.researcheridABG-8202-2021
dc.date.accessioned2025-02-13T05:34:35Z
dc.date.available2025-02-13T05:34:35Z
dc.date.issued2024-12-31
dc.description.abstractThis study- a secondary analysis of data from a randomized, observer-blinded, non-inferiority study among volunteers between 18-55 y old in T & uuml;rkiye- evaluated the impact of previous SARS-CoV-2 infection before the first dose of inactive TURKOVAC on post-vaccine local and systemic adverse events (AEs) comparing with CoronaVac. Of 1266 participants analyzed, 27.7% had a previous COVID-19 history. Local and systemic AEs were observed in 37.3% and 39% of the participants. The frequency of AEs was slightly higher in the first 30 minutes and 24 hours among participants with a COVID-19 history; none were severe. 1203 participants had a second dose vaccination, and 27.3% had a history of COVID-19. The frequencies of local and systemic AEs after the second dose were similar between those with and without a COVID-19 history. The TURKOVAC and CoronaVac showed similar frequencies of local and systemic AEs in the first 30 minutes after vaccination.
dc.description.sponsorshipTHE HEALTH INSTITUTES OF TURKI (TUSEB) TSB-11568-VAC-COV-TUR-F3.01
dc.identifier.doi10.1080/21645515.2024.2346388
dc.identifier.issn2164-5515
dc.identifier.issue1
dc.identifier.scopus2-s2.0-85197121324
dc.identifier.urihttps://doi.org/10.1080/21645515.2024.2346388
dc.identifier.urihttps://hdl.handle.net/11452/50334
dc.identifier.volume20
dc.identifier.wos001255690600001
dc.indexed.wosWOS.SCI
dc.language.isoen
dc.publisherTaylor & Francis Inc
dc.relation.journalHuman Vaccines & Immunotherapeutics
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subject1st
dc.subjectTurkovac
dc.subjectCoronavac
dc.subjectInactive covid-19 vaccine
dc.subjectSafety
dc.subjectCovid-19
dc.subjectPrevious infection
dc.subjectAdverse events
dc.subjectScience & technology
dc.subjectLife sciences & biomedicine
dc.subjectBiotechnology & applied microbiology
dc.subjectImmunology
dc.subjectBiotechnology & applied microbiology
dc.titleThe impact of previous sars-cov-2 infection on post-vaccine adverse events in individuals vaccinated with turkovac or coronavac -inactivated covid-19 vaccines
dc.typeArticle
dspace.entity.typePublication
local.contributor.departmentTıp Fakültesi/ Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Ana Bilim Dalı.
local.indexed.atWOS
local.indexed.atScopus
relation.isAuthorOfPublication4fb46529-3295-4383-97b1-7c494ff32c24
relation.isAuthorOfPublication.latestForDiscovery4fb46529-3295-4383-97b1-7c494ff32c24

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
Akalın_vd_2024.pdf
Size:
809.73 KB
Format:
Adobe Portable Document Format